Is Sparsentan approved by the FDA?

Yes, Sparsentan, marketed under the brand name Filspari, is FDA approved. The FDA granted accelerated approval to Sparsentan for its ability to reduce proteinuria (excess protein in the urine) in adults with primary immunoglobulin A nephropathy. The approval is contingent upon the results of confirmatory clinical trials to verify its clinical benefit.

Mechanism of Action: 

Sparsentan works by targeting pathways involved in the progression of kidney disease, helping to lower the levels of protein in the urine. This action is crucial for patients with primary immunoglobulin A nephropathy, as high protein levels in the urine are a marker of kidney damage.

Common Side Effects:

• Dizziness
• Swelling of hands, legs, ankles, and feet
• Anemia (low red blood cells)

Serious Side Effects:

• Allergic reactions (hives, difficulty breathing, swelling of face, lips, tongue, or throat)
• Serious liver problems (nausea, vomiting, loss of appetite, right-sided upper stomach pain, tiredness, weight loss, jaundice, dark urine, fever, or itching)
• Light-headed feeling, like you might pass out
• Kidney problems (swelling, urinating less, feeling tired or short of breath)
• High blood potassium (nausea, weakness, tingly feeling, chest pain, irregular heartbeats, loss of movement)
• Fluid retention (shortness of breath, swelling, rapid weight gain, especially in the face and midsection)

Warnings and Precautions:

• Pregnancy: Sparsentan can cause birth defects. Effective birth control must be used while taking this medication and for at least one month after the last dose. A negative pregnancy test is required before starting treatment.
• Liver Problems: Sparsentan may cause serious liver issues. Regular liver function tests are necessary.
• Other Medications: Some drugs should not be used with Sparsentan, such as certain blood pressure medications, and other cardiovascular agents. Always inform your doctor about all other medications you are taking.

Usage Instructions:

• Take Sparsentan once daily, preferably at the same time each day.
• Swallow the tablet whole with a full glass of water before a meal.
• Drink plenty of fluids while taking Sparsentan.
• Do not stop taking Sparsentan suddenly without consulting your doctor.
• Store Sparsentan at room temperature, away from moisture and heat, in its original container.

Dosage Information:

• Initial dose: 200 mg orally once a day for 14 days.
• Maintenance dose: Increase to 400 mg orally once a day, as tolerated, following the initial dose period.

Conclusion: 

Sparsentan (Filspari) is an FDA-approved medication for the treatment of primary immunoglobulin A nephropathy in adults. Its approval is based on its effectiveness in reducing proteinuria, a key indicator of kidney disease progression. Patients must adhere to the prescribed regimen and take necessary precautions to manage potential side effects and drug interactions. Regular medical monitoring is essential to ensure safe and effective use of Sparsentan.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!